Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Rhea-AI Summary

Sunesis Pharmaceuticals (NASDAQ: SNSS) announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on October 24-25, 2020. The presentation will focus on the PDK1 inhibitor SNS-510, showcasing its synergy with standard therapies in solid tumors and hematologic cancers. The complete abstract will be available on Sunesis' website during the event. Sunesis continues to advance its pipeline, including SNS-510, which is in IND-enabling studies, and vecabrutinib, which completed a Phase 1b trial for advanced B cell malignancies.

Positive

• Poster presentation scheduled for October 24, 2020, highlights SNS-510's synergy with established therapies.
• SNS-510 is currently in IND-enabling studies, indicating progress towards potential clinical use.
• Vecabrutinib has completed Phase 1b trial in patients with advanced B cell malignancies, showing continued development in the pipeline.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32^nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 24-25, 2020 in a virtual format.

The details for the poster presentation are as follows:

Date and Time: October 24, 2020, 9:00 a.m. ET
Abstract Title: PDK1 inhibitor SNS-510 shows synergy with standard cancer therapies in solid tumor and hematologic cancer models
Session Name: Molecular Targeted Agents
Publication Number: 163

The full abstract can be viewed here, and the poster will be made available on the Sunesis website at the time of the presentation.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including first-in-class PDK1 inhibitor SNS-510. SNS-510 is in IND-enabling studies and vecabrutinib has completed a Phase 1b trial in patients with advanced B cell malignancies.

For additional information on Sunesis, please visit www.sunesis.com.

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to Sunesis’ continued development and potential of its kinase inhibitor pipeline, including SNS-510; the therapeutic potential of SNS-510 and vecabrutinib. Words such as “expect,” “will,” “look forward,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These risk factors are discussed under "Risk Factors" in Sunesis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and Sunesis' other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Sunesis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902

Par Hyare Sunesis Pharmaceuticals Inc. 650-266-3784

FAQ

What is the purpose of the SNS-510 presentation at the EORTC-NCI-AACR Symposium?

The presentation will showcase the synergy of PDK1 inhibitor SNS-510 with standard cancer therapies.

When is the SNS-510 poster presentation scheduled?

The poster presentation is scheduled for October 24, 2020, at 9:00 a.m. ET.

What are the next steps for SNS-510 after the presentation?

SNS-510 is in IND-enabling studies, which could lead to clinical trials.

What were the results of vecabrutinib's Phase 1b trial?

Vecabrutinib has completed a Phase 1b trial for patients with advanced B cell malignancies.

What is Sunesis Pharmaceuticals focusing on in its drug development?

Sunesis is focused on developing novel targeted inhibitors for hematologic and solid cancers.